NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
611 Gävleborg |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 59 | 0.8% | 20 | 0.3% | 9 | 0.1% | . | . | . | . | 4 | 0.1% | 7248 | 98.7% | 7340 | 100.0% |
ASCUS | 66 | 13.3% | 84 | 17.0% | 85 | 17.2% | 2 | 0.4% | 1 | 0.2% | 8 | 1.6% | 249 | 50.3% | 495 | 100.0% |
LSIL | 11 | 13.6% | 17 | 21.0% | 30 | 37.0% | . | . | . | . | 1 | 1.2% | 22 | 27.2% | 81 | 100.0% |
Unclear atypia | . | . | 1 | 10.0% | 6 | 60.0% | 3 | 30.0% | . | . | . | . | . | . | 10 | 100.0% |
ASC-H | 4 | 21.1% | 3 | 15.8% | 10 | 52.6% | . | . | 2 | 10.5% | . | . | . | . | 19 | 100.0% |
HSIL | 4 | 8.9% | 5 | 11.1% | 32 | 71.1% | . | . | 2 | 4.4% | . | . | 2 | 4.4% | 45 | 100.0% |
Totalt | 144 | 1.8% | 130 | 1.6% | 172 | 2.2% | 5 | 0.1% | 5 | 0.1% | 13 | 0.2% | 7521 | 94.1% | 7990 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M80703, M81403 |